Baader Bank Aktiengesellschaft Boosts Holdings in Regeneron Pharmaceuticals, Inc. $REGN

Baader Bank Aktiengesellschaft boosted its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 138.7% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 6,811 shares of the biopharmaceutical company’s stock after buying an additional 3,958 shares during the quarter. Baader Bank Aktiengesellschaft’s holdings in Regeneron Pharmaceuticals were worth $5,262,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Norges Bank bought a new position in Regeneron Pharmaceuticals in the fourth quarter worth approximately $1,012,296,000. Price T Rowe Associates Inc. MD grew its position in shares of Regeneron Pharmaceuticals by 142.2% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,949,797 shares of the biopharmaceutical company’s stock valued at $1,504,991,000 after acquiring an additional 1,144,887 shares during the period. Nuveen LLC increased its stake in shares of Regeneron Pharmaceuticals by 71.1% in the 4th quarter. Nuveen LLC now owns 2,010,517 shares of the biopharmaceutical company’s stock worth $1,551,858,000 after purchasing an additional 835,240 shares in the last quarter. Wellington Management Group LLP increased its stake in shares of Regeneron Pharmaceuticals by 8,620.0% in the 4th quarter. Wellington Management Group LLP now owns 664,465 shares of the biopharmaceutical company’s stock worth $512,881,000 after purchasing an additional 656,845 shares in the last quarter. Finally, AQR Capital Management LLC raised its holdings in Regeneron Pharmaceuticals by 528.7% in the 3rd quarter. AQR Capital Management LLC now owns 721,354 shares of the biopharmaceutical company’s stock worth $405,596,000 after purchasing an additional 606,612 shares during the period. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Price Performance

NASDAQ:REGN opened at $672.15 on Tuesday. The company has a quick ratio of 2.96, a current ratio of 3.57 and a debt-to-equity ratio of 0.06. The business’s 50-day simple moving average is $640.18 and its two-hundred day simple moving average is $717.26. The stock has a market cap of $71.06 billion, a PE ratio of 16.38, a P/E/G ratio of 1.50 and a beta of 0.24. Regeneron Pharmaceuticals, Inc. has a 52 week low of $541.00 and a 52 week high of $821.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share for the quarter, topping analysts’ consensus estimates of $8.91 by $0.56. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.The firm had revenue of $3.61 billion during the quarter, compared to analyst estimates of $3.48 billion. During the same quarter in the prior year, the company posted $8.22 earnings per share. The business’s quarterly revenue was up 19.0% compared to the same quarter last year. As a group, analysts forecast that Regeneron Pharmaceuticals, Inc. will post 37.12 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Thursday, June 4th. Shareholders of record on Wednesday, May 20th were issued a dividend of $0.94 per share. This represents a $3.76 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date of this dividend was Wednesday, May 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 9.16%.

Analysts Set New Price Targets

REGN has been the topic of several analyst reports. Truist Financial lowered their target price on Regeneron Pharmaceuticals from $778.00 to $769.00 and set a “buy” rating on the stock in a research report on Tuesday, July 7th. Piper Sandler reduced their price target on Regeneron Pharmaceuticals from $855.00 to $854.00 and set an “overweight” rating for the company in a research report on Thursday, July 9th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research note on Wednesday, June 24th. Barclays lowered their price objective on Regeneron Pharmaceuticals from $923.00 to $917.00 and set an “overweight” rating on the stock in a research report on Thursday, April 30th. Finally, HSBC cut their price objective on Regeneron Pharmaceuticals from $990.00 to $880.00 and set a “buy” rating for the company in a research note on Monday, July 6th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $787.67.

Trending Headlines about Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Negative Sentiment: Multiple law firms, including Bernstein Liebhard, Levi & Korsinsky, the Schall Law Firm, the DJS Law Group, Faruqi & Faruqi, and Bronstein, Gewirtz & Grossman, announced or reminded investors about a class action lawsuit against Regeneron Pharmaceuticals, Inc. (REGN), with a lead plaintiff deadline of September 14, 2026. These notices suggest potential litigation risk and uncertainty for shareholders. Article Title
• Negative Sentiment: The lawsuit coverage increases headline risk and could weigh on sentiment until more details emerge about the alleged claims and the company’s response. Article Title
• Neutral Sentiment: The company previously reported strong quarterly results, including earnings and revenue that beat expectations, which remains a supportive backdrop for the stock even as legal issues dominate near-term trading. MarketBeat

Insider Transactions at Regeneron Pharmaceuticals

In other news, Director Arthur F. Ryan sold 200 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Thursday, July 2nd. The shares were sold at an average price of $650.15, for a total transaction of $130,030.00. Following the sale, the director owned 17,303 shares in the company, valued at $11,249,545.45. This trade represents a 1.14% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.97% of the stock is currently owned by company insiders.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.